25/08/2026
Most people accept 10,000 steps a day as the benchmark for cardiovascular health. The number didn't come from a clinical trial. It came from a 1965 marketing campaign in Japan.
In 1965, the Yamasa Tokei company began selling a step counter called the Manpo-kei. The name translates literally to "10,000-step meter." The number was a brand identity, picked because the Japanese character for 10,000 resembled a person walking. There was no underlying mortality study. No randomized trial. The 10,000 target became a global health norm because the device was successful and the number was memorable.
The actual mortality data tells a different story.
Lee and colleagues (2019, JAMA Internal Medicine) measured step counts in 16,741 older women using accelerometers and tracked all-cause mortality over four years. Compared with the lowest step quartile (around 2,700 steps per day), women averaging 4,400 steps had significantly lower mortality. Risk continued declining with more steps. Then it leveled off. The plateau was around 7,500 steps per day. Beyond that, additional steps showed no further mortality benefit in this population.
Saint-Maurice and colleagues (2020, JAMA) measured 4,840 US adults aged 40 and older. Compared with 4,000 steps per day, taking 8,000 steps was associated with roughly half the all-cause mortality risk. Twelve thousand steps showed further benefit, though the marginal gain after 8,000 was smaller than the gain from 4,000 to 8,000.
Paluch and colleagues (2022, Lancet Public Health) pooled 15 international cohorts including 47,471 adults. They found the dose-response curve plateaued at 6,000-8,000 steps per day for adults 60 and older, and at 8,000-10,000 for adults under 60. The age-dependent plateau is the most replicable finding across the literature.
What this means in practice. If you are over 60, the data suggests most of the mortality benefit accrues by 7,000-8,000 steps per day. If you are under 60, that benefit window extends a bit further, into the 8,000-10,000 range. Going beyond your population's plateau is fine. It is just not adding measurable mortality benefit at the population level. The number to chase isn't 10,000. The number to clear is closer to 7,000 for most adults.
A few caveats. These are observational cohort studies, not randomized trials. Reverse causality is a concern at the low end, where people who walk less may walk less because they are already sick. The studies adjusted for known confounders but residual confounding likely remains. The data is also strongest for all-cause mortality. Step targets for specific outcomes like cardiovascular event reduction, weight management, or cognitive performance may differ. Stepping intensity, separately analyzed, did not predict mortality independently of total daily steps in any of these studies.
10,000 is a round number that came from a 1965 product name. It is not a research-derived target. The mortality data shows the curve flattens earlier than that for most adults, and the practical implication is that consistent walking at moderate volume captures most of the available benefit. The number on your wearable is not the goal.
Lee et al., JAMA Internal Medicine
2019 Saint-Maurice et al., JAMA, 2020
Paluch et al., Lancet Public Health, 2022
